Literature DB >> 6542151

Progression from hypertrophic obstructive cardiomyopathy to typical dilated cardiomyopathy-like features in the end stage.

H Fujiwara, T Onodera, M Tanaka, H Shirane, H Kato, J Yoshikawa, G Osakada, S Sasayama, C Kawai.   

Abstract

An autopsied patient who had shown typical dilated cardiomyopathy (DCM)-like feature in the end stage of familial obstructive hypertrophic cardiomyopathy (HCM) is presented. The patient, a 38-year-old male, had 2 sisters with HCM. Six years before death, the echocardiogram revealed marked asymmetric septal hypertrophy (ASH) with systolic anterior motion (SAM). The ventricular septum (VS) to left ventricular posterior wall (LVPW) ratio was 19 mm/10 mm and LVEDd was 47 mm. Subsequently, the signs and symptoms of congestive heart failure became progressively worse and DCM-like findings appeared insidiously. Two months before death, the echocardiogram revealed LV dilatation (LVEDd = 55 mm) with diffuse poor contraction, no ASH (VS/LVPW = 7 mm/9 mm) and no SAM. At autopsy, the heart weighed 480g and showed dilated LV hypertrophy with normal wall thickness (VS/LVPW = 9 mm/13 mm). Massive fibrosis (30% in the VS), diffuse disarray (18% in the VS) and severe narrowing of the intramural small arteries and arterioles were found in the middle and outer thirds of the VS and the anterior LV wall. The extramural coronary arteries were not stenosed. The insidious progression from HCM to typical DCM-like feature related to the chronic progression of necrosis and massive fibrosis, due to severe stenosis of the intramural coronary artery. The data indicate that patients diagnosed clinically as DCM may be HCM, especially in those with family history of HCM.

Entities:  

Mesh:

Year:  1984        PMID: 6542151     DOI: 10.1253/jcj.48.1210

Source DB:  PubMed          Journal:  Jpn Circ J        ISSN: 0047-1828


  8 in total

1.  Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy.

Authors:  R Thaman; J R Gimeno; R T Murphy; T Kubo; B Sachdev; J Mogensen; P M Elliott; W J McKenna
Journal:  Heart       Date:  2005-07       Impact factor: 5.994

2.  Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy.

Authors:  K L Vikstrom; S M Factor; L A Leinwand
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

3.  Comparative study of 201Tl-scintigraphic image and myocardial pathologic findings in patients with dilated cardiomyopathy.

Authors:  L X Li; R Nohara; K Okuda; R Hosokawa; T Hata; M Tanaka; A Matsumori; M Fujita; N Tamaki; J Konishi; S Sasayama
Journal:  Ann Nucl Med       Date:  1996-08       Impact factor: 2.668

4.  Luminal narrowing of coronary capillaries in human hypertrophic hearts: an ultrastructural morphometrical study using endomyocardial biopsy specimens.

Authors:  G Takemura; Y Takatsu; H Fujiwara
Journal:  Heart       Date:  1998-01       Impact factor: 5.994

5.  Cardiac troponin T Arg92Trp mutation and progression from hypertrophic to dilated cardiomyopathy.

Authors:  N Fujino; M Shimizu; H Ino; K Okeie; M Yamaguchi; T Yasuda; H Kokado; H Mabuchi
Journal:  Clin Cardiol       Date:  2001-05       Impact factor: 2.882

6.  Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy.

Authors:  M Shimizu; N Sugihara; Y Kita; K Shimizu; Y Horita; K Nakajima; J Taki; R Takeda
Journal:  Br Heart J       Date:  1992-02

7.  Pathological features of hypertrophic cardiomyopathy without asymmetrical septal hypertrophy.

Authors:  M Tanaka; H Fujiwara; C Kawai
Journal:  Br Heart J       Date:  1986-09

8.  Implantation of ventricular assist devices in hypertrophic cardiomyopathy with left ventricular systolic dysfunction.

Authors:  Nobuichiro Yagi; Osamu Seguchi; Hiroki Mochizuki; Kensuke Kuroda; Seiko Nakajima; Takuya Watanabe; Masanobu Yanase; Naoki Tadokoro; Satsuki Fukushima; Tomoyuki Fujita; Norihide Fukushima
Journal:  ESC Heart Fail       Date:  2021-10-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.